On March 19, 2024, Allarity Therapeutics, Inc. announced the entry into an At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. Under this agreement, Allarity Therapeutics may offer and sell shares of its common stock up to an aggregate offering price of $947,000. The sales of these shares will be conducted through Ascendiant Capital Markets, LLC, as the agent, and will be offered pursuant to a prospectus supplement filed with the SEC on the same date. The offering will be subject to market conditions and regulatory limitations, and may be terminated by either party with 10 days' notice. Allarity Therapeutics has agreed to pay a 3.0% commission on gross proceeds from the sale of shares to the agent, along with reimbursement for certain legal fees and expenses. The offering is set to terminate on the earlier of the sale of all shares, March 19, 2026, or upon agreement termination.

On March 19, 2024, Allarity Therapeutics, Inc. announced the entry into an At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. Under this agreement, Allarity Therapeutics may offer and sell shares of its common stock up to an aggregate offering price of $947,000. The sales of these shares will be conducted through Ascendiant Capital Markets, LLC, as the agent, and will be offered pursuant to a prospectus supplement filed with the SEC on the same date. The offering will be subject to market conditions and regulatory limitations, and may be terminated by either party with 10 days' notice. Allarity Therapeutics has agreed to pay a 3.0% commission on gross proceeds from the sale of shares to the agent, along with reimbursement for certain legal fees and expenses. The offering is set to terminate on the earlier of the sale of all shares, March 19, 2026, or upon agreement termination.